FiercePharma1d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
GlobalData on MSN23h
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...
Nektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90M
Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...
bovnews13d
The Nektar Therapeutics Stock Thriller: Decoding the Mystery Behind NKTR’s Recent Movements
On Wednesday, Nektar Therapeutics (NKTR) stock saw a decline, ending the day at $1.41 which represents a decrease of $-0.03 or -2.08% from the prior close of $1.44. The stock opened at $1.44 and ...
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...
ETF Daily News3d
Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts
Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.
EurekAlert!13d
Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300
Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of ...